Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines

In Vivo

Volumn 19, Issue 6, 2005, Pages 1061-1070

  Lee, Yi Min ^a   Wu, Tai Hsien ^a  

^a CHUNGTAI INST HLTH SCI TECHNOL   (Taiwan)

Author keywords

2 acetylaminofluorene; 2 aminofluorene; 5 methoxypsoralen; N acetyltransferase

Indexed keywords

2 FLUORENYLAMINE; ARYLAMINE ACETYLTRANSFERASE; BERGAPTEN; N (2 FLUORENYL)ACETAMIDE;

ACETYLATION; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL COMMUNICATION; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOCUMENTATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME REGULATION; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; METABOLIC RATE; NONHUMAN; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE; STOMACH TUMOR; TUMOR CELL LINE;

EID: 27744463445     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Hein DW, Doll MA, Xiao GH and Feng Y: Prostate expression of N-acetyltransferase 1 (NAT1) and (NAT2) in rapid and slow acetylator congenic Syrian hamster. Pharmacogenetics 13: 159-167, 2003.
2. Le ML, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, Seifried A, Custer LJ, Chang W, Lum-Jones A and Donlon T: Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1259-1266, 2001.
3. Bitsch A, Klohn PC, Hadjiolov N, Bergmann O and Neumann HG: New insights into carcinogenesis of the classical model arylamine 2-acetylaminofluorene. Cancer Lett 1: 223-227, 1999.
4. Wang CY, Jones RF, Debiec-Rychter M, Soos G and Haas GP: Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. Anticancer Res 22: 3529-3535, 2002.
5. McQueen CA and Chau B: Neonatal ontogeny of murine arylamine N-acetyltransferases: implications for arylamine genotoxicity. Toxicol Sci 73: 279-286, 2003.
6. Sim E, Pinter K, Mushtaq A, Upton A, Sandy J, Bhakta S and Noble M: Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. Biochim Soc Trans 31: 615-619, 2003.
7. Weber WW: The Acetylator Genes and Drug Response. New York, Oxford University Press, pp. 21-55, 1987.
8. Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM and McManus ME: Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 54: 19-29, 2000.
9. Chung JG, Levy GN and Weber WW: Distribution of 2-aminofluorene and p-aminobenzoic acid N-acetyltransferase activity in tissues of C57BL/6J rapid and B6.A-NatS slow acetylator congenic mice. Drug Metab Dispos 21: 1057-1063, 1993.
10. Blum M, Grant DM, McBride OW, Heim H and Meyer UA: Human arylamine N-acetyltransferase genes: isolation, characterization, chromosomal localization, and functional expression. DNA Cell Bio 9: 193-203, 1990.
11. Hein DW: Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 30: 65-77, 2002.
12. Hein DW, Leff MA, Ishibe N, Sinha R, Frazier HA, Doll MA, Xiao OH, Weinrich MC and Caporaso NE: Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen 40: 161-167, 2002.
13. Grant DM, Blum M, Beer M and Meyer UA: Monomorphic and polymorphic human arylamine N-acetyltransferase: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39: 184-191, 1991.
14. Spielberg SP: N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 24: 509-519, 1996.
15. Furet Y, Bechtel Y, Le Guellec C, Bechtel PR, Autret-Leca E and Paintaud G: Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. Therapie 57: 427-431, 2002.
16. Roberts-Thomson IC, Butler WJ and Ryan P: Meat, metabolic genotypes and risk for colorectal cancer. Eur J Cancer Prev 8: 207-211, 1999.
17. Chen J, Stampfer MJ, Hough HL, Garcia-Closas M, Willett WC, Hennekens CH, Kelsey KT and Hunter DJ: A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 58: 3307-3311, 1998.
18. Kirlin WG, Ogolla F, Andrews AF, Trinidad A, Ferguson RJ, Yerokun T, Mpezo M and Hein DW: Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients. Cancer Res 51: 549-555, 1991.
19. Inatomi H, Katoh T, Kawamoto T and Matsumoto T: NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 6: 446-454, 1999.
20. Lu KH, Cheng KC, Hsia TC, Lin KL, Wu CL, Chou MC and Chung HG: Paclitaxel affects the amounts of the N-acetylation of 2-aminofluorene and DNA-2-aminofluorene adduct formation in Sprague-Dawley rats. In Vivo 17: 137-144, 2003.
21. Lin JG, Chen GW, Su CC, Hung CF, Yang CC, Lee JH and Chung JG: Effects of garlic components diallyl sulfide and diallyl disulfide on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in human promyelocytic leukemia cells. Am J Chin Med 30: 315-325, 2002.
22. Yeh CC, Chung JG, Wu HC, Chang HL, Yeh FT and Hung CF: Effects of aspirin on arylamine N-acetyltransferase activity and DNA adducts in human bladder tumour cells. J Appl Toxicol 19: 389-394, 1999.
23. Chung JG, Chen GW, Yang MD, Wang DY, Hung CF, Lin WC and Chang HL: Hydrocortisone affects the N-acetylation of 2-aminofluorene and DNA-2-aminofluorene adduct formation in Sprague-Dawley rats. Anticancer Res 22: 1641-1647, 2002.
24. Aune T, Vanderslice RR, Croft JE, Dybing E, Bend JR and Philpot RM: Deactylation to 2-aminofluorene as a major initial reaction in the microsomal metabolism of 2-acetylaminofluorene to mutagenic products in preparations from rabbit lung and liver. Cancer Res 45: 5859- 5866, 1985.
25. Heflich RH and Neft RE: Genetic toxicity of 2-acetylaminofluorene, 2-aminofluorene and some of their metabolites and model metabolites. Mutat Res 318: 73-114, 1994.
26. Hsia TC, Chung JG, Lu HF, Ho HC, Yang CC, Lu KH and Hung CF: The effect of paclitaxel on 2-aminofluorene-DNA adducts formation and arylamine N-acetyltransferase activity and gene expression in human tumor cells (A549). Food Chem Toxicol 40: 697-703, 2002.
27. Holme JA and Soderlund EJ: Modulation of genotoxic and cytotoxic effects of aromatic amines in monolayers of rat hepatocytes. Cell Biol Toxicol 1: 95-110, 1984.
28. Bitsch A, Klohn PC, Hadjiolov N, Bergmann O and Neumann HG: New insights into carcinogenesis of the classical model arylamine 2-acetylaminofluorene. Cancer Lett 143: 223-227, 1999.
29. Beier RC: Natural pesticides and bioactive components in foods. Rev Environ Contam Toxicol 113: 47-137, 1990.
30. Diawara MM and Trumble JT: Linear furanocoumarins. In: Handbook on Plant and Fungal Toxicants. D'Mello JPF (ed.). Boca Raton, Florida, CRC Press, pp. 175-189, 1997.
31. Li RZ, He YQ, Chiao M, Xu Y, Zhang QB, Meng JR, Gu Y and Ge LP: Studies of the active constituents of the Chinese drug "duhuo" Angelica pubescents. Yao-Hsueh-Hsueh-Pao 24: 546-551, 1989.
32. Zarebska Z, Waszkowska E, Caffieri S and Dall'Acqua F: PUVA (psoralen + UVA) photochemotherapy: processes triggered in the cells. II Farmaco 55: 515-520, 2000.
33. Turegun M, Ozturk S and Selmanpakoglu N: An unusual cause of burn injury: unsupervised use of drugs that contain psoralens. J Burn Care Rehabil 20: 2-5, 1999.
34. Musajo L and Rodighiero G: The skin-photosensitizing furanocoumarins. Experientia 18: 153-200, 1962.
35. Van Scott EJ: Therapy of psoriasis. JAMA 235: 197-198, 1976.
36. Scott BR, Pathak MA and Mohm GR: Molecular and genetic basis of furanocoumarin reactions. Mutat Res 39: 29-74, 1976.
37. Pathak MA and Fitzpatrick TB: The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. Photochem Photobiol B 14: 3-33, 1992.
38. Chadwick CA, Potten CS, Cohen M and Young AR: The time of onset and duration of 5-methoxypsoralen photochemoprotection from UVR-mduced DNA damage in human skin. Br J Dermatol 131: 483-494, 1994.
39. McNeely W and Goa KL: 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo. Drugs 56: 667-690, 1998.
40. Colombo G, Zucchi A, Allegra F, Colombo P, Zani F and Santi P: In vitro and in vivo study of 5-methoxypsoralen skin concentration after topical application. Skin Pharmacol Appl Skin Physiol 16: 130-136, 2003.
41. Chandler R, Diawara MM, Caprioglio H, Chavez KJ and Williams DE: Examination of psoralens-induced photodermatitis in Wistar rats under scanning electron microscopy. J Nat Toxins 8: 167-177, 1999.
42. Diawara MM, Williams DE, Oganesian A and Spitsbergen J: Dietary psoralens induce hepatotoxicity in C57 mice. J Nat Toxins 9: 179-195, 2000.
43. Diawara MM, Allison T, Kulkosky P and Williams DE: Psoralen-induced growth inhibition in Wistar rats. Cancer Lett 19: 159-160, 1997.
44. Diawara MM, Chavez KJ, Simpleman D, Williams DE, Franklin MR and Hoyer PB: The psoralens adversely affect reproductive function in male Wistar rats. Reprod Toxicol 15: 137-144, 2001.
45. Walter JF, Gange RW and Mendelson IR: Psoralen-containing sunscreen induces phototoxicity and epidermal ornithine decarboxylase activity. J Am Acad Dermatol 6: 1022-1027, 1982.
46. Lee YM, Chen SF, Wu TH and Chung JG: Oral administration of 5-methoxypsoralen affects the distribution and metabolism of 2-aminofluorene in Sprague-Dawley rats. In Vivo 16: 201-214, 2002.
47. Miller EC and Miller JA: Searches for the ultimate chemical carcinogens and their reaction with cellular macromolecules. Cancer 47: 2327-2332, 1981.
48. Hammons GJ, Guengerich FP, Weis CC, Beland FA and Kadlubar FF: Metabolic oxidation of carcinogenic arylamines by rat, dog, and human hepatic microsomes and by purified flavin-containing and cytochrome P-450 monooxygenases. Cancer Res 45: 3578-3585, 1985.
49. Badawi AF, Stem SJ, Lang NP and Kadlubar FF: Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. Prog Clin Biol Res 395: 109-140, 1996.
50. Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H and Kawamoto T: Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 1: 1967-1976, 2004.
51. Koenigs LL and Trager WF: Mechanism-based inactivation of P450 2A6 by furanocoumarins. Biochemistry 37: 10047-10061, 1998.
52. Koenigs LL and Trager WF: Mechanism-based inactivation of cytochrome P450 2BI by 8-methoxypsoralen and several other furanocoumarins. Biochemistry 37:13184-13193, 1998.
53. Tsukino H, Kuroda Y, Qiu D, Nakao H, Imai H and Katoh T: Effects of cytochrome (CYP) 2A6 gene deletion and CYP 2E1 genotypes on gastric adenocarcinoma. Int J Cancer 1: 425-428, 2002.
54. Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF and Lin DX: Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 95: 96-101, 2001.
55. Cai Y, Bear-Dubowska W, Ashwood-Smith MJ, Ceska O, Tachibana S and DiGiovanni J: Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem Res Toxicol 9: 729-736, 1996.
56. Hecht SS: Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91: 1194-1210, 1999.
57. Ho PC and Saville DJ: Inhibition of CYP3A4 by grapefruit flavonoids furanocoumarins and related compounds. J Pharm Pharmaceut Sci 4: 217-227, 2001.
58. Malhotra S, Bailey DG, Paine MF and Watkins PB: Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furanocoumarins. Clin Pharmacol Ther 69: 14-23, 2001.
59. Debiec-Rychter M, Land SJ and King CM: Histological localization of messenger RNAS for rat acetyltransferases that acetylate serotonin and genotoxic arylamines. Cancer Res 56: 1517-1525, 1996.
60. Ding X and Kaminsky LS: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43: 149-173, 2003.
61. Slattery ML, Samowtiz W, Ma K, Murtaugh M, Sweeney C, Levin TR and Neuhausen S: CYP1A1, cigarette smoking, and colon and rectal cancer. Am J Epidemiol 160: 842-852, 2004.
62. Suzuki S, Muroishi Y, Nakanishi I and Oda Y: Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol 39: 220-230, 2004.
63. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS: Identification of glucocorticoid inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80: 1029-1036, 1987.
64. Thompson PD, Jurutka PW, Whitfield GK, Myskowski SM, Eichhorst KR, Dominguez CE, Haussler CA and Haussler MR: Liganded VDR induces CYP34A in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 299: 730-738, 2002.
65. Yokose T, Doy M, Kakiki M, Horie T, Matsuzaki Y and Mukai K: Expression of cytochrome P450 3A4 in foveolar epithelium with intestinal metaplasia of the human stomach. Jpn J Cancer Res 89: 1028-1032, 1998.
66. Einisto P, Watanabe M, Ishidate M and Nohmi T: Mutagenicity of 30 chemicals in S. typhimurium possessing different nitroreductase or O-acetyltransferase activities. Mutat Res 259: 95-102, 1991.